Patent Application for Free LIGHT Detection and Treatment
Summary
The USPTO has published a patent application (US20260085112A1) from Avalo Therapeutics, Inc. for methods of detecting and treating conditions associated with elevated free LIGHT using anti-LIGHT antibodies. The application covers methods for diagnosing conditions like acute lung injury, ARDS, and Crohn's Disease.
What changed
This document is a published patent application from Avalo Therapeutics, Inc. detailing methods for detecting and treating conditions related to elevated free LIGHT. The application, identified as US20260085112A1, describes diagnostic techniques for biological samples and therapeutic approaches using anti-LIGHT antibodies. Specific conditions mentioned include acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and Crohn's Disease, with potential applications in viral infections.
As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future developments in diagnostics and therapeutics within the pharmaceutical and biotechnology sectors. Companies involved in related research or treatment areas should monitor the progress of this patent application and any subsequent granted patents, as they may impact intellectual property landscapes and market exclusivity for certain treatments.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and Treatment Involving Excess Free LIGHT
Application US20260085112A1 Kind: A1 Mar 26, 2026
Assignee
Avalo Therapeutics, Inc.
Inventors
Garry A. Neil, Inbal Zafir-Lavie
Abstract
The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.
CPC Classifications
C07K 16/241 A61K 31/706 A61K 39/3955 A61K 45/06 A61P 1/00 A61P 29/00 A61P 31/14 G01N 33/6863 A61K 2039/505 C07K 2317/565 C07K 2317/90 G01N 2333/525
Filing Date
2025-05-09
Application No.
19203608
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.